Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $3.6 million.

  • Xeris Biopharma Holdings' Change in Accured Expenses rose 884.65% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 67.57%. This contributed to the annual value of $3.6 million for FY2024, which is 162.34% up from last year.
  • According to the latest figures from FY2024, Xeris Biopharma Holdings' Change in Accured Expenses is $3.6 million, which was up 162.34% from -$5.9 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Change in Accured Expenses ranged from a high of $12.6 million in FY2021 and a low of -$11.4 million during FY2022.
  • In the last 3 years, Xeris Biopharma Holdings' Change in Accured Expenses had a median value of -$5.9 million in 2023 and averaged -$4.5 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Change in Accured Expenses soared by 292.25% in 2021, and later tumbled by 190.67% in 2022.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Change in Accured Expenses stood at $3.2 million in 2020, then spiked by 292.25% to $12.6 million in 2021, then crashed by 190.67% to -$11.4 million in 2022, then surged by 48.57% to -$5.9 million in 2023, then soared by 162.34% to $3.6 million in 2024.